Trial Profile
A Phase 1 Multicenter, Open-Label, Dose-Escalation and Dose-Expansion Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, Immunogenicity and Antitumor Activity of MSC-1 in Patients With Advanced Solid Tumors
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 24 Apr 2023
Price :
$35
*
At a glance
- Drugs MSC 1 (Primary)
- Indications Colorectal cancer; Head and neck cancer; Non-small cell lung cancer; Ovarian cancer; Pancreatic cancer; Solid tumours
- Focus Adverse reactions; Therapeutic Use
- Sponsors AstraZeneca; Northern Biologics
- 20 Apr 2023 Status changed from discontinued to completed.
- 28 Apr 2020 Results presented at the 111th Annual Meeting of the American Association for Cancer Research - I
- 02 Jan 2020 Status changed from active, no longer recruiting to discontinued.